Second-Quarter 2012 Financial Reports Show Pfizer, Novartis Down; Merck Up - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Second-Quarter 2012 Financial Reports Show Pfizer, Novartis Down; Merck Up


ePT--the Electronic Newsletter of Pharmaceutical Technology

Pharmaceutical industry leaders Pfizer, Novartis, and Merck—among others—released second-quarter 2012 results, emphasizing growth of new products and strength in emerging markets.

Pfizer’s second-quarter 2012 revenues were $15.1 billion, down 9% from the second-quarter 2011, the company stated in a recent press release. US revenues were down 15% compared with the year-ago quarter, primarily due to the loss of exclusivity of Lipitor on Nov. 30, 2011. International revenues, which represented 62% of total revenues for the quarter, were down 5% compared to the year-ago quarter, primarily due to the unfavorable impact of foreign exchange, said the release. Emerging market unit revenues grew 14% compared with the year-ago quarter, primarily due to volume growth in China and Russia. Pfizer reaffirmed its 2012 financial guidance, noting its continued confidence, financial flexibility, and significant cost savings generated by cost-reduction and productivity initiatives, said Frank D’Amelio, Pfizer CFO, in the release.

Novartis’ group net sales, including its Pharmaceuticals division and Alcon eye care division, were $14.3 billion in the second-quarter 2012, down 4% from second-quarter 2011, stated the company in a press release. Currency had a negative impact of 5%, resulting in 1% growth on a constant-currency basis, said the release. Growth from recently launched products more than offset the loss associated with the Diovan patent expiration. Recently launched products now represent 29% of the company’s group net sales compared with 25% last year, demonstrating Novartis’ continued focus on portfolio rejuvenation. The group secured eight significant regulatory milestones in the second quarter as well, which included European CHMP recommendations for Afinitor in breast cancer, Jakavi in myelofibrosis, and Seebri Breezhaler in COPD, commented Novartis CEO Joseph Jimenez.

Merck’s global sales were $12.3 billion in second-quarter 2012, up 1%, or 5% excluding foreign exchange, from second-quarter 2011, said the company in a press release. Second-quarter pharmaceutical sales grew 5% after excluding 2011 sales of Remicade and Simponi transferred to Johnson & Johnson through a settlement agreement. Emerging markets accounted for 18% of pharmaceutical sales in the second quarter. China, in particular, grew 27% in the second quarter, including 4% from foreign exchange.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here